Iminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramine

Taro Kishi, Shinji Matsunaga, Yuki Matsuda, Nakao Iwata Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan Background: We conducted a meta-analysis of the iminodibenzyl antipsychotics carpipramine, clocapramine, and mosapramine, which are classified as second-ge...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Kishi T, Matsunaga S, Matsuda Y, Iwata N
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://doaj.org/article/f678f081ddd74b73888cfcf2a2d9d80c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:f678f081ddd74b73888cfcf2a2d9d80c
record_format dspace
spelling oai:doaj.org-article:f678f081ddd74b73888cfcf2a2d9d80c2021-12-02T06:32:38ZIminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramine1178-2021https://doaj.org/article/f678f081ddd74b73888cfcf2a2d9d80c2014-12-01T00:00:00Zhttp://www.dovepress.com/iminodibenzyl-class-antipsychotics-for-schizophrenia-a-systematic-revi-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021 Taro Kishi, Shinji Matsunaga, Yuki Matsuda, Nakao Iwata Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan Background: We conducted a meta-analysis of the iminodibenzyl antipsychotics carpipramine, clocapramine, and mosapramine, which are classified as second-generation antipsychotics (SGAs) for schizophrenia treatment.Methods: We searched data that had been published in PubMed, the Cochrane Library databases, PsycINFO, CiNii, and the Japan Medical Abstracts Society up to August 29, 2014. Randomized controlled trials that compared iminodibenzyl antipsychotics with other antipsychotics in patients with schizophrenia were included. Odds ratios and standardized mean differences were evaluated.Results: We included four randomized controlled trials on carpipramine (number of patients [n]=290), six on clocapramine (n=1,048), and five on mosapramine (n=986) in the meta-analysis. There were no significant differences in the response rates or in the discontinuation rates either between carpipramine and the other pooled antipsychotics or between clocapramine and the other pooled antipsychotics. On the Positive and Negative Syndrome Scale, mosapramine’s positive subscale scores were superior to those of the other pooled antipsychotics (standard mean of difference =−0.22); however, on that same scale, there were no significant differences in total scores, negative scores, general subscale scores, response rates, or the discontinuation rates between mosapramine and the other pooled antipsychotics. Furthermore, the incidences of extrapyramidal symptoms and of hyperprolactinemia were significantly greater with mosapramine than with the other pooled antipsychotics.Conclusion: The pharmacological profiles of carpipramine and clocapramine, which are classified as SGAs, were similar to those of first-generation antipsychotics because there were no significant differences in efficacy and safety outcomes. However, mosapramine was associated with a greater risk of extrapyramidal symptoms and hyperprolactinemia than the other SGAs were, although it may be beneficial for the improvement of positive symptoms. Keywords: carpipramine, clocapramine, mosapramine, schizophrenia, meta-analysisKishi TMatsunaga SMatsuda YIwata NDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2014, Iss default, Pp 2339-2351 (2014)
institution DOAJ
collection DOAJ
language EN
topic Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Kishi T
Matsunaga S
Matsuda Y
Iwata N
Iminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramine
description Taro Kishi, Shinji Matsunaga, Yuki Matsuda, Nakao Iwata Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan Background: We conducted a meta-analysis of the iminodibenzyl antipsychotics carpipramine, clocapramine, and mosapramine, which are classified as second-generation antipsychotics (SGAs) for schizophrenia treatment.Methods: We searched data that had been published in PubMed, the Cochrane Library databases, PsycINFO, CiNii, and the Japan Medical Abstracts Society up to August 29, 2014. Randomized controlled trials that compared iminodibenzyl antipsychotics with other antipsychotics in patients with schizophrenia were included. Odds ratios and standardized mean differences were evaluated.Results: We included four randomized controlled trials on carpipramine (number of patients [n]=290), six on clocapramine (n=1,048), and five on mosapramine (n=986) in the meta-analysis. There were no significant differences in the response rates or in the discontinuation rates either between carpipramine and the other pooled antipsychotics or between clocapramine and the other pooled antipsychotics. On the Positive and Negative Syndrome Scale, mosapramine’s positive subscale scores were superior to those of the other pooled antipsychotics (standard mean of difference =−0.22); however, on that same scale, there were no significant differences in total scores, negative scores, general subscale scores, response rates, or the discontinuation rates between mosapramine and the other pooled antipsychotics. Furthermore, the incidences of extrapyramidal symptoms and of hyperprolactinemia were significantly greater with mosapramine than with the other pooled antipsychotics.Conclusion: The pharmacological profiles of carpipramine and clocapramine, which are classified as SGAs, were similar to those of first-generation antipsychotics because there were no significant differences in efficacy and safety outcomes. However, mosapramine was associated with a greater risk of extrapyramidal symptoms and hyperprolactinemia than the other SGAs were, although it may be beneficial for the improvement of positive symptoms. Keywords: carpipramine, clocapramine, mosapramine, schizophrenia, meta-analysis
format article
author Kishi T
Matsunaga S
Matsuda Y
Iwata N
author_facet Kishi T
Matsunaga S
Matsuda Y
Iwata N
author_sort Kishi T
title Iminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramine
title_short Iminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramine
title_full Iminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramine
title_fullStr Iminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramine
title_full_unstemmed Iminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramine
title_sort iminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramine
publisher Dove Medical Press
publishDate 2014
url https://doaj.org/article/f678f081ddd74b73888cfcf2a2d9d80c
work_keys_str_mv AT kishit iminodibenzylclassantipsychoticsforschizophreniaasystematicreviewandmetaanalysisofcarpipramineclocapramineandnbspmosapramine
AT matsunagas iminodibenzylclassantipsychoticsforschizophreniaasystematicreviewandmetaanalysisofcarpipramineclocapramineandnbspmosapramine
AT matsuday iminodibenzylclassantipsychoticsforschizophreniaasystematicreviewandmetaanalysisofcarpipramineclocapramineandnbspmosapramine
AT iwatan iminodibenzylclassantipsychoticsforschizophreniaasystematicreviewandmetaanalysisofcarpipramineclocapramineandnbspmosapramine
_version_ 1718399911127416832